Four children with terminal brain cancer saved by new cell therapy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- TAA T-cell therapy kept four children alive years after treatment for incurable brain cancers, with three showing no evidence of disease in a phase-I trial of 33 children and young adults.
- One child with DIPG survived more than two years despite typical survival being under a year for the disease, a finding team member Catherine Bollard called a signal of efficacy.
- Three responders with recurrent glioblastoma, astroblastoma, or medulloblastoma had previously failed up to 17 rounds of chemotherapy and radiation, and remain disease-free between two and five years later.
- The therapy trains a patient's own T-cells to recognize three protein antigens common in pediatric brain tumors without any genetic engineering, distinguishing it from CAR T-cell therapy used in blood cancers.
- Side effects were milder than CAR T-cell therapy—mostly fatigue and headache—though two patients experienced tumor swelling, possibly linked to large pre-existing tumor volumes.
- Bollard said the team is launching two follow-up trials: one combining the therapy with ultrasound to open the blood-brain barrier, and another personalizing antigen targeting via tumor genetic sequencing.
- Tim Hassall of Queensland Children's Hospital said the field had failed to move the survival needle for 20 years, calling the approach "a whole different treatment area opening up."
Why it matters: For families of children diagnosed with DIPG or recurrent pediatric brain tumors—conditions with near-zero survival under current standards—this is the first credible efficacy signal from a cellular therapy against solid pediatric brain tumors. Because TAA T-cell therapy avoids the genetic modification of CAR T-cell therapy and may work broadly for solid tumors, it could open a treatment class rather than just one drug.
